GSK Enters Oncology Market with New Therapies for Gynaecological Cancers

GlaxoSmithKline Pharmaceuticals has launched its oncology segment in India, introducing precision therapies Jemperli (dostarlimab) and Zejula (niraparib) for gynaecological cancers. The MOVE addresses a critical gap in women's cancer care, with endometrial and ovarian cancer rates projected to rise sharply by 2045.

Jemperli stands as India's sole approved PD-1 immunotherapy for advanced endometrial cancer, while Zejula is the only PARP inhibitor approved for first-line maintenance across all biomarker types. These therapies offer alternatives to chemotherapy, which often carries toxicity and poor long-term outcomes for late-stage patients.

The launch reinforces GSK's commitment to specialty medicines in India, where gynaecological cancers rank among the most prevalent women's malignancies. Nearly 25% of endometrial cancer cases present at advanced stages, underscoring the need for innovative treatment options.